000028:SSEChina National Accord Medicines Corporation Ltd. Analysis

The stock trades at CNY 21.52, comfortably above the 20‑day (CNY 20.23) and 50‑day (CNY 20.90) simple moving averages but still below the 200‑day average of CNY 22.60. Technicals show a bullish MACD crossover with a positive histogram (+0.21) and a signal line in negative territory, suggesting short‑term upward momentum. Volume has been rising, reinforcing the strength of recent price moves. Nonetheless, the model‑derived trend direction is flagged as bearish and the price sits just under the near‑term resistance at CNY 22.08, indicating limited upside in the immediate horizon. The 30‑day volatility of 33 % is high, implying sizable price swings.
On the valuation side, the stock’s trailing P/E of 12x is far below the industry average of 28x, and the P/B of 0.70 signals a substantial margin of safety. The discounted cash‑flow estimate of CNY 43.7 suggests the market is pricing the company at roughly a 13 % discount to intrinsic value. Analyst price targets (mean CNY 24.39, median CNY 26.36) are well above the current level, supporting the upside case. The dividend yield of 2.9 % with a modest payout ratio of 19 % is comfortably covered by earnings and cash flow. Debt is low (debt‑to‑equity 18.7 %) and the balance sheet holds CNY 5.2 bn in cash, limiting financial risk. The company’s ROE of 5 % and modest revenue contraction (‑2.6 %) point to a value‑oriented, rather than high‑growth, profile. Combined with a beta of 0.16, the stock exhibits low systematic risk despite its high short‑term volatility.